Volume OXygenation index in predicting the efficacy of early non-invasive ventilation in patients with acute hypoxic respiratory failure: A multicenter study
Xiaoyi Liu , Hui Liu , Lijuan Chen , Jun Duan , Hui Ran , Lili Chen , Rui Zhou , Xiangde Zheng
{"title":"Volume OXygenation index in predicting the efficacy of early non-invasive ventilation in patients with acute hypoxic respiratory failure: A multicenter study","authors":"Xiaoyi Liu , Hui Liu , Lijuan Chen , Jun Duan , Hui Ran , Lili Chen , Rui Zhou , Xiangde Zheng","doi":"10.1016/j.hrtlng.2025.03.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The Volume OXygenation (VOX) index was initially designed to predict treatment failure of high-flow nasal cannula therapy. However, its predictive power for non-invasive ventilation (NIV) remains uncertain.</div></div><div><h3>Objectives</h3><div>To evaluate the predictive capability of the VOX index regarding treatment failure in patients undergoing NIV.</div></div><div><h3>Methods</h3><div>This retrospective study was conducted in three hospitals from September 2017 to September 2021. Patients with acute hypoxic respiratory failure (AHRF) who underwent early NIV treatment were categorized into high-risk and low-risk groups based on the 2-hour NIV VOX Youden index.</div></div><div><h3>Results</h3><div>At 2 h of NIV, the area under the receiver operating characteristic curve for predicting NIV failure using the VOX index was 0.843 (95 % CI 0.805–0.882). Using a VOX value threshold of 20.45 to predict NIV failure, the sensitivity was 69.1 %, and the specificity was 94.4 %. Following NIV treatment, the low-risk group had a lower intubation rate (7.98 % vs. 77 %, <em>P</em> < 0.05) and mortality rate (4.79 % vs. 17.5 %, <em>P</em> < 0.05).</div></div><div><h3>Conclusion</h3><div>In early NIV treatment for AHRF, the VOX index obtained after 2 h of NIV demonstrates a strong predictive power for NIV failure. Patients with a VOX value > 20.45 have a low probability of NIV failure, suggesting that it can be used as an evaluation index to assess the efficacy of NIV.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"72 ","pages":"Pages 42-47"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart & Lung","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147956325000603","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The Volume OXygenation (VOX) index was initially designed to predict treatment failure of high-flow nasal cannula therapy. However, its predictive power for non-invasive ventilation (NIV) remains uncertain.
Objectives
To evaluate the predictive capability of the VOX index regarding treatment failure in patients undergoing NIV.
Methods
This retrospective study was conducted in three hospitals from September 2017 to September 2021. Patients with acute hypoxic respiratory failure (AHRF) who underwent early NIV treatment were categorized into high-risk and low-risk groups based on the 2-hour NIV VOX Youden index.
Results
At 2 h of NIV, the area under the receiver operating characteristic curve for predicting NIV failure using the VOX index was 0.843 (95 % CI 0.805–0.882). Using a VOX value threshold of 20.45 to predict NIV failure, the sensitivity was 69.1 %, and the specificity was 94.4 %. Following NIV treatment, the low-risk group had a lower intubation rate (7.98 % vs. 77 %, P < 0.05) and mortality rate (4.79 % vs. 17.5 %, P < 0.05).
Conclusion
In early NIV treatment for AHRF, the VOX index obtained after 2 h of NIV demonstrates a strong predictive power for NIV failure. Patients with a VOX value > 20.45 have a low probability of NIV failure, suggesting that it can be used as an evaluation index to assess the efficacy of NIV.
期刊介绍:
Heart & Lung: The Journal of Cardiopulmonary and Acute Care, the official publication of The American Association of Heart Failure Nurses, presents original, peer-reviewed articles on techniques, advances, investigations, and observations related to the care of patients with acute and critical illness and patients with chronic cardiac or pulmonary disorders.
The Journal''s acute care articles focus on the care of hospitalized patients, including those in the critical and acute care settings. Because most patients who are hospitalized in acute and critical care settings have chronic conditions, we are also interested in the chronically critically ill, the care of patients with chronic cardiopulmonary disorders, their rehabilitation, and disease prevention. The Journal''s heart failure articles focus on all aspects of the care of patients with this condition. Manuscripts that are relevant to populations across the human lifespan are welcome.